4 results
To assess the treatment effect of BEZ235 relative to everolimus on progression free survival in patients with advanced pancreatic neuroendocrine tumors who have not been previously treated with an mTOR inhibitor.
To determine whether treatment with BEZ235 plus best supportive care prolongs PFS compared with placebo plus best supportive care in patients with advanced pancreas NET, after failure of a mTOR inhibitor therapy
Efficacy of BEZ235 on objective response rate according to RECIST 1.1
The purpose of this study is to investigate how quickly and to what extent JNJ-64417184 is absorbed and eliminated from the body when it is given together with drugs that reduce the stomach acidity. The study also investigates how safe the new…